Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Salicylic Acid
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Eris Pharmaceuticals
Deal Size : $33.2 million
Deal Type : Divestment
Details : Under the agreement, Dr. Reddy’s divests certain non-core brands including Hydroheal, Gris ODT, Revilus, Revibra, Avarta, Salicylix (salicylic acid), Clearz, Acrofy and Aquaderm, in dermatology in India to Eris Lifesciences.
Product Name : Salicylix
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 16, 2023
Lead Product(s) : Salicylic Acid
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Eris Pharmaceuticals
Deal Size : $33.2 million
Deal Type : Divestment
Lead Product(s) : Salicylic Acid
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Salicylic acid helps soften, lift, and clear away flakes of skin on psoriasis plaques. It helps to control the symptoms of psoriasis and provides relief from itching, irritation and redness.
Product Name : DERMAdoctor
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2023
Lead Product(s) : Salicylic Acid
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salicylic Acid
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Research Bridge Partners
Deal Size : $2.0 million
Deal Type : Financing
Asalyxa Bio Closes Seed Financing to Advance Lead Program into First-in-Human Clinical Studies
Details : Proceeds from the financing will be used to advance Asalyxa Bio's lead development candidate, ASX-100, into first-in-human clinical trials.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 23, 2021
Lead Product(s) : Salicylic Acid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Research Bridge Partners
Deal Size : $2.0 million
Deal Type : Financing
Lead Product(s) : Salicylic Acid
Therapeutic Area : Podiatry
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Investigation to Evaluate The Orkla Corn Plaster
Details : Undisclosed
Product Name : Orkla Corn Plaster
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 23, 2020
Lead Product(s) : Salicylic Acid
Therapeutic Area : Podiatry
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salicylic Acid
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Orange Grove Bio
Deal Size : Undisclosed
Deal Type : Funding
Details : ASX-100 is a novel, spherical polymer particle that degrades into salicylic acid – an active metabolite of aspirin – and a food additive that is listed as GRAS (generally regards as safe) by the FDA. Seed funding will be used in first-in-human trials...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 25, 2020
Lead Product(s) : Salicylic Acid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Orange Grove Bio
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Salicylic Acid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Main Line Health
Deal Size : Inapplicable
Deal Type : Inapplicable
17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 23, 2012
Lead Product(s) : Salicylic Acid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Main Line Health
Deal Size : Inapplicable
Deal Type : Inapplicable